Zydus Lifesciences Limited
ZYDUSLIFE · 532321 · Healthcare · Pharmaceuticals
- Market cap
- Rs 1,18,203 Cr
- P/E
- 26.40x
- P/B
- 4.36x
- 52W high / low
- Rs 1,232.1 / Rs 835.5
Our computed operating_margin (22.79%) diverges from BSE's own published figure (63.55%) by more than 100%. BSE's figure is a different, BSE-computed number (not necessarily TTM, standalone-only) — treat as a cross-check/fallback signal, not proof either figure is wrong. Our computed net_margin (16.06%) diverges from BSE's own published figure (46.03%) by more than 100%. BSE's figure is a different, BSE-computed number (not necessarily TTM, standalone-only) — treat as a cross-check/fallback signal, not proof either figure is wrong.
About Zydus Lifesciences
Zydus Lifesciences Limited is listed on the NSE under the symbol ZYDUSLIFE and on the BSE under scrip code 532321. It is classified in the Healthcare sector, industry: Pharmaceuticals. It is a constituent of BSE 200, NIFTY 100, NIFTY 200, NIFTY 500, NIFTY Next 50 and NIFTY Pharma. The company listed on 18 Apr 2000 and has a face value of Rs 1.
The latest available end-of-day price is Rs 1,184.4 (+0.76% on the day), for a market capitalisation of Rs 1,18,203 Cr. Trailing P/E is 26.40x and price-to-book is 4.36x. The 52-week range is Rs 835.5 to Rs 1,232.1. The latest price is 88% of the way from the 52-week low to the 52-week high.
Against the 15-company comparison set from the official BSE basic industry Pharmaceuticals, its market capitalisation is 1.1 times the peer median of Rs 1,09,706 Cr, and its P/E of 26.40x compares with a peer median of 36.40x. The comparison set is chosen mechanically from the exchange classification; it is not a ranking.
Latest annual results
For FY26 (year ended 31 Mar 2026), Zydus Lifesciences Limited reported revenue of Rs 27,148 Cr and net profit of Rs 5,124 Cr, with a net margin of 18.87% and earnings per share of Rs 50.09 (consolidated statements).
Year-on-year change: revenue +17.64%; net profit +9.65%; EPS +11.39%. Three-year compound annual growth rate: revenue +16.65%; net profit +34.79%.
At the same date the balance sheet shows total assets of Rs 52,407 Cr, shareholders' equity of Rs 27,111 Cr, total debt of Rs 11,770 Cr, cash of Rs 855 Cr, a debt-to-equity ratio of 0.43 and operating cash flow of Rs 2,117 Cr.
On a trailing-twelve-month basis the filings add up to revenue of Rs 28,592 Cr, net income of Rs 4,593 Cr and a net margin of 16.06%.
Shareholding pattern
In the shareholding pattern for 30 Sept 2026, Zydus Lifesciences Limited's ownership is split: promoters 75.01%; foreign institutional investors (FIIs) 7.05%; domestic institutional investors (DIIs) 11.28%; retail and other shareholders 6.66%.
Compared with the filing for 30 Jun 2026: promoter holding 0.00 percentage points; FII holding +0.17 percentage points; DII holding +0.01 percentage points.
The same filing lists reported promoter pledge of 0.00% and 3,82,067 shareholders on record.
Recent filings and corporate actions
200 BSE corporate announcements were filed by Zydus Lifesciences Limited in the past twelve months; the most frequent category is "Company Update" (175). The most recent is "Q2 FY27 post results earning call details" (Company Update), filed on 24 Oct 2026.
The disclosed corporate-action timeline lists 8 entries: dividend (5), buyback (3). The latest is a dividend (Final Dividend - Rs. - 1.0000) with ex-date 24 Jul 2026.
Figures are raw disclosures from official NSE/BSE and SEBI filings plus mechanically computed ratios, restated in words. This is research data, not investment advice, a rating or a recommendation; DalalOS is not a SEBI-registered investment advisor.
More
Peer comparison
Official BSE basic industry: Pharmaceuticals. Limited to companies within a 0.1x–10x market-cap band.
Edit columns
| Sun Pharmaceutical Industries Limited | Rs 1,761 | Rs 4,22,517 Cr | Rs 62,141 Cr | Rs 12,117 Cr | 34.94x | 15.53% |
| Divi's Laboratories Limited | Rs 9,664 | Rs 2,56,096 Cr | Rs 11,682 Cr | Rs 2,925 Cr | 87.69x | 18.44% |
| Torrent Pharmaceuticals Limited | Rs 4,580 | Rs 1,55,015 Cr | Rs 15,654 Cr | Rs 2,156 Cr | 73.16x | 27.30% |
| Laurus Labs Limited | Rs 2,244 | Rs 1,21,232 Cr | Rs 7,323 Cr | Rs 1,091 Cr | — | 22.38% |
| Zydus Lifesciences LimitedThis company | Rs 1,184.4 | Rs 1,18,203 Cr | Rs 29,052 Cr | Rs 4,593 Cr | 26.40x | 17.68% |
| Dr. Reddy's Laboratories Limited | Rs 1,345 | Rs 1,12,308 Cr | Rs 34,353 Cr | Rs 2,760 Cr | 40.02x | 7.84% |
| Cipla Limited | Rs 1,358 | Rs 1,09,706 Cr | Rs 28,855 Cr | Rs 2,854 Cr | 37.86x | 8.83% |
| Mankind Pharma Limited | Rs 2,469.3 | Rs 1,01,982 Cr | Rs 15,705 Cr | Rs 2,264 Cr | 45.45x | 14.78% |
| Aurobindo Pharma Limited | Rs 1,659.9 | Rs 95,511 Cr | Rs 35,625 Cr | Rs 3,711 Cr | 25.94x | 10.53% |
| Lupin Limited | Rs 1,989.9 | Rs 90,988 Cr | Rs 30,442 Cr | Rs 5,551 Cr | 16.44x | 27.89% |
| Glenmark Pharmaceuticals Limited | Rs 2,339 | Rs 66,007 Cr | Rs 18,236 Cr | Rs 1,798 Cr | 36.71x | 15.46% |
| Alkem Laboratories Limited | Rs 5,079 | Rs 60,719 Cr | Rs 15,681 Cr | Rs 2,204 Cr | 28.15x | 16.72% |
| Biocon Limited | Rs 351.9 | Rs 57,346 Cr | Rs 17,638 Cr | Rs 416 Cr | — | 1.78% |
| Abbott India Limited | Rs 26,145 | Rs 55,558 Cr | Rs 7,295 Cr | Rs 1,615 Cr | 34.41x | 35.85% |
| Gland Pharma Limited | Rs 3,074.5 | Rs 50,717 Cr | Rs 7,045 Cr | Rs 1,129 Cr | 44.88x | 11.57% |
| Median | Rs 2,244 | Rs 1,09,706 Cr | Rs 15,705 Cr | Rs 2,760 Cr | 36.40x | 16.72% |
Peers are selected mechanically from the official BSE industry hierarchy and current market-cap band. This is a comparison set, not a ranking or recommendation.
Companies related to Zydus Lifesciences
Same official industry (Pharmaceuticals)
- Sun Pharmaceutical Industries LimitedSUNPHARMA · Market cap Rs 4,22,517 Cr
- Divi's Laboratories LimitedDIVISLAB · Market cap Rs 2,56,096 Cr
- Torrent Pharmaceuticals LimitedTORNTPHARM · Market cap Rs 1,55,015 Cr
- Laurus Labs LimitedLAURUSLABS · Market cap Rs 1,21,232 Cr
- Dr. Reddy's Laboratories LimitedDRREDDY · Market cap Rs 1,12,308 Cr
- Cipla LimitedCIPLA · Market cap Rs 1,09,706 Cr
- Mankind Pharma LimitedMANKIND · Market cap Rs 1,01,982 Cr
- Aurobindo Pharma LimitedAUROPHARMA · Market cap Rs 95,511 Cr
Other Healthcare companies of a similar market capitalisation
- Apollo Hospitals Enterprise LimitedAPOLLOHOSP · Market cap Rs 1,17,916 Cr
- Lupin LimitedLUPIN · Market cap Rs 90,988 Cr
- Max Healthcare Institute LimitedMAXHEALTH · Market cap Rs 82,837 Cr
- Glenmark Pharmaceuticals LimitedGLENMARK · Market cap Rs 66,007 Cr
- Alkem Laboratories LimitedALKEM · Market cap Rs 60,719 Cr
- Biocon LimitedBIOCON · Market cap Rs 57,346 Cr
- Fortis Healthcare LimitedFORTIS · Market cap Rs 56,992 Cr
- Abbott India LimitedABBOTINDIA · Market cap Rs 55,558 Cr
Companies are grouped mechanically from the exchange classification and listed by market capitalisation. This is a comparison set, not a ranking or recommendation.